Major lung complications of systemic sclerosis

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Background:

• Systemic sclerosis (SSc) is a severe autoimmune disease with high mortality, primarily due to internal organ complications.
• Lung disease, specifically fibrosis and pulmonary arterial hypertension (PAH), represents the leading cause of death in SSc patients.
• Effective management of SSc-associated lung disease hinges on accurately identifying patients with severe pathology and predicting treatment response.

Purpose of the Study:

• To review recent advancements in the diagnosis and management of lung fibrosis and PAH in Systemic Sclerosis.
• To highlight evolving strategies for risk stratification and therapeutic interventions for SSc-related lung complications.

Main Methods:

• Review of recent clinical trial results and management guidelines for SSc-associated lung fibrosis.
• Analysis of current approaches for identifying and managing pulmonary arterial hypertension in SSc patients.
• Synthesis of evidence supporting novel and established treatment modalities for SSc lung disease.

Main Results:

• Refined tools for assessing the risk of progression and severity of SSc-associated lung fibrosis are now available.
• Clinical trials support immunosuppression, including high-intensity regimens and autologous stem cell transplantation for lung fibrosis.
• Approved therapies for SSc-associated PAH demonstrate good long-term outcomes, emphasizing the importance of early risk identification and appropriate patient management.

Conclusions:

• Significant progress has been made in managing lung fibrosis and PAH in Systemic Sclerosis.
• Early detection of high-risk individuals and tailored treatment strategies are crucial for improving outcomes in SSc lung disease.
• Ongoing research continues to explore novel therapeutic options for SSc-related pulmonary complications.